在患有帕金森病的老年患者中坚持和坚持服用利沃多巴辅助药物:使用日本索赔数据库进行的回顾性队列研究
Masahiro Nagai1, Michinori Koebis2, Kotaro Sasaki3
1Department of Neurology and Clinical Pharmacology, Ehime University, Ehime, Japan.
Frontiers in neurology
|April 25, 2025
概括
超过一半的日本帕金森病患者在一年内停止了服用利沃多巴辅助药物的治疗. 然而,治疗坚持率仍然很高,这表明该老年人群的药物管理良好.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 帕金森病 (PD) 的管理通常涉及levodopa与辅助药物结合.
- 了解治疗持续性和坚持性对于优化患者的治疗结果至关重要.
研究的目的:
- 调查日本帕金森病患者的治疗持久性和对利沃多巴辅助药物的坚持.
- 探索人口因素与治疗持续性/坚持性之间的关系.
主要方法:
- 一项使用日本医疗保险索赔数据库的纵向回顾性研究.
- 包括2020年12月至2021年11月期间新处方的抗帕金森病 (anti-PD) 药物以及利沃多巴的患者.
- 对17种抗PD药物队列的分析,通过多变量分析评估1年治疗持久性和坚持性.
主要成果:
- 总共分析了7,605名患者 (平均年龄为77.2岁,43.6%是男性).
- 一年治疗持续率为44.8%,在药物队列中存在显著差异 (28.6%至59.5%). 佐尼萨米德和萨菲纳米德的持久性更高.
- 按覆盖日数比例 (≥80%) 衡量的遵守率很高 (总体为96.9%). 同时服用抗PD药物的数量与不持续性有很强的关联.
结论:
- 在一年内,超过一半的新增抗PD补充剂被停止服用利沃多巴.
- 基于处方补充数据的治疗坚持率在帕金森病患者中特别高,包括老年人.
- 诸如同时服用抗PD药物的数量等因素会影响治疗的持续性.
相关概念视频
01:24Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
01:15Parkinson's Disease: Overview
310
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310
01:28Drug Therapy
28
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
28
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
3.6K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
3.6K
01:26Psychosis: Goals of Pharmacotherapy
95
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
95
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
41
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
41